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Introduction: Serious Streptococcus pneumoniae infections, encompassing pneumonia, 
bacteremia, and meningitis, are a major cause of mortality. However, literature regarding 
mortality is often limited to invasive pneumococcal disease, excluding pneumonia. This study 
sought to identify predictors of mortality among adults with serious pneumococcal disease, 
including pneumonia and invasive pneumococcal disease. 
Methods: This was a nested case-control study of unvaccinated older Veterans with positive S. 
pneumoniae cultures (blood, cerebrospinal fluid, respiratory) admitted to Veterans Affairs 
medical centers nationally between 2002 and 2011. Patients vaccinated against pneumococcal 
disease were excluded. Using multivariable logistic regression, predictors of 30-day mortality 
were identified, including patient demographics, comorbidities during admission, and medical 
history within the previous year. 
Results: Among 9,468 patients, there were 9,730 serious pneumococcal infections; 1,764 
(18.6%) resulted in death within 30 days (cases), whereas 7,966 did not (controls). Pneumonia 
accounted for half (49.4%, n=871) of all deaths. Mortality predictors consistent with vaccine 
recommendations included dialysis (during hospitalization, OR=3.35, 95% CI=2.37, 4.72), 
moderate to severe liver disease (during hospitalization, OR=2.47, 95% CI=1.53, 3.99; within 1 
year, OR=1.49, 95% CI=1.01, 2.20), and neutropenia (during hospitalization, OR=2.67, 95% 
CI=1.32, 5.42). Predictors not included in current recommendations included dementia (during 
hospitalization, OR=1.8, 95% CI=1.23, 2.61) and neurologic disorders (during hospitalization, 
OR=1.86, 95% CI=1.42, 2.45; within 1 year, OR=1.28, 95% CI=1.02, 1.59). 
Conclusions: Several mortality predictors among unvaccinated Veterans with serious 
pneumococcal disease were consistent with pneumococcal vaccine recommendations, including 
3 
organ or immune system dysfunction–related conditions. Other predictors, including neurologic 
disorders or dementia, may warrant expanded vaccination recommendations. 
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INTRODUCTION 
Streptococcus pneumoniae is a leading cause of morbidity and mortality worldwide, much of 
which is the result of serious pneumococcal infections, including pneumonia, bacteremia, and 
meningitis.1,2 Although invasive pneumococcal disease, which encompasses bacteremia and 
meningitis, results in more than 15,000 hospitalizations and a mortality of at least 15%, much of 
the burden of serious pneumococcal disease is related to pneumonia.2 In the U.S. alone, an 
estimated 900,000 individuals develop pneumococcal pneumonia annually, resulting in 
approximately 400,000 hospitalizations.1–3 Though mortality for pneumococcal pneumonia is 
only 5%–7% overall, this includes less severe pneumonias managed in the outpatient setting.5 
Mortality in adults aged 65 years and older and those requiring hospitalization is approximately 
15%, as these individuals may be more susceptible to complications, including development of 
bacteremia.1–4 
 
Despite the burden of pneumococcal pneumonia, studies assessing predictors of mortality 
associated with serious pneumococcal disease have focused primarily on patients with invasive 
pneumococcal disease only, excluding patients with nonbacteremic pneumonia.1,2 As such, the 
purpose of this study was to identify independent predictors of mortality among unvaccinated 
adults with serious pneumococcal disease, including pneumonia and invasive pneumococcal 
disease. 
 
METHODS 
The IRB and the Research and Development Committee of the Providence Veterans Affairs 
Medical Center approved this study. 
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The Veterans Health Administration is the largest healthcare system in the U.S., composed of 
152 medical centers along with 1,400 outpatient facilities and community living centers.10 The 
electronic medical record utilized by the Veterans Health Administration captures both inpatient 
and outpatient visits dating back to 1999. The Veterans Affairs databases have been described 
previously.11,12 An analytic database was created from numerous Veterans Affairs databases 
capturing patient care, including demographics, inpatient stays, outpatient visits, pharmacy 
dispensings and administrations, health factors, surgeries and procedures, laboratory and 
microbiology results, immunizations, and vital status. 
 
Study Population 
This was a national nested case-control study of Veterans aged ≥50 years requiring inpatient care 
for serious pneumococcal disease (bacteremia, meningitis, pneumonia) between January 1, 2002 
and December 31, 2011.11 Adults aged ≥50 years were selected as they are at the highest risk of 
developing these serious pneumococcal infections.5 Positive S. pneumoniae sputum, blood, and 
cerebrospinal fluid cultures were identified using microbiology datas.11 Pneumonia was 
identified by positive sputum culture in addition to a pneumonia ICD-9 diagnosis code. From 
this cohort, individuals who had not received the pneumococcal vaccine, as determined from 
pharmacy, procedure, and immunization status data, within 5 years of the positive culture were 
selected for inclusion. 
 
Cases were defined as those who died from any cause within 30 days of positive culture, and 
controls were those alive at 30 days. All available controls were included as mortality was 
expected to be approximately 20%, resulting in a 1:4 ratio of cases to controls, and matching was 
not utilized as all demographic and clinical characteristics were assessed as predictors.13,14 Using 
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ICD-9 and procedure codes, current comorbidities and medical history were determined, and 
defined as the presence of disease states during the index admission and within 1 year of the 
positive culture date, respectively. Use of immunosuppressant medications was also assessed 
using pharmacy data. Immunosuppressant medication use was defined as corticosteroid, 
monoclonal antibody, or antineoplastic agent use within 30 days prior to positive culture date. 
 
Potential predictors of mortality included patient demographics, disease states present during the 
admission as well as those documented within 1 year prior to positive culture, the presence of 
immunosuppressant medications, presence of invasive disease, and length of stay. All current 
Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination, such 
as age, immunodeficiency, diabetes, chronic lung disease, chronic heart disease, liver disease, 
and alcoholism, were included as potential predictors in order to quantify risk of mortality to 
unvaccinated individuals with these conditions. 
 
Statistical Analysis 
Independent predictors of 30-day all-cause mortality were identified utilizing a backward manual 
stepwise logistic regression model.14 As part of the univariate analysis, variables were deemed to 
be included in the subsequent multivariable analysis at a p-value <0.10.14 Significant variables 
from the univariate analysis were then removed in a stepwise fashion from the multivariable 
model until all remaining variables within the model demonstrated a Wald p-value <0.05.14 
Variables in the predictor model were assessed for multicollinearity. All statistical analyses were 
performed with SAS, version 9.2. 
 
RESULTS 
7 
There were 14,511 episodes of serious pneumococcal infections, of which 4,781 (33%) episodes 
involved those who had received the pneumococcal vaccine in the previous 5 years and were 
therefore excluded. Of the 9,468 identified unvaccinated patients, there were 9,730 episodes of 
serious pneumococcal infections; 1,764 (18.6%) died within 30 days of culture (cases) and 7,966 
did not die (controls). Pneumonia (62%, n=6,075), bacteremia (26%, n=2,554), and bacteremic 
pneumonia (11%, n=1,060) were the most common infections, with a 30-day mortality rate of 
14%, 23%, and 29%, respectively. A total of 41 episodes (0.4%) of pneumococcal meningitis 
occurred during the study period. Approximately half (50.6%, n=893) of those who died within 
30 days had invasive pneumococcal disease. Overall 30-day mortality in patients with invasive 
disease was 24%. Characteristics of cases and controls are described in detail in Table 1. 
Compared with those alive 30 days after positive culture, those who died within 30 days were 
significantly (p<0.05) older (mean age, 71 [SD=11] years vs 67 [SD=11] years) and, in the 
previous year, were significantly more likely to have a history of infections, including 
pneumococcal infections (38.9% vs 28.3%), pneumonia (35.4% vs 24%), bacteremia (6.2% vs 
2.7%), urinary tract infections (15.1% vs 7.3%), and skin or soft tissue infections (15.9% vs 
10.7%). Several comorbidities present during the index admission were significantly (p<0.05) 
more common among cases compared with controls, including heart failure (18.9% vs 13.1%), 
cardiac arrhythmias (28.5% vs 18.8%), chronic respiratory disease (32.8% vs 39%), chronic 
renal disease (11.1% vs 7.3%), mild hepatic disease (7.9% vs 5.1%), moderate or severe hepatic 
disease (3.2% vs 0.8%), and dialysis (5.9% vs 1.9%). Additionally, cases were significantly more 
likely to have received an immunocompromising medication within 30 days of admission 
(28.2% vs 22.5%) and have a history of chronic conditions, including heart failure (27.7% vs 
16.6%), coronary artery disease (34.6% vs 25.1%), chronic respiratory disease (51.6% vs 
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45.3%), diabetes mellitus (27% vs 21.5%), or an immunocompromising condition (42.3% vs 
31.8%). 
 
Based on the multivariable regression analysis, predictors of 30-day all-cause mortality present 
within 1 year of culture that are also current ACIP recommendations for pneumococcal 
vaccination included metastatic malignancy (Table 2; OR 1.53), mild hepatic disease (OR=1.35), 
moderate to severe hepatic disease (OR=1.49), and myocardial infarction (OR=1.31). Significant 
predictors of mortality present during hospitalization that are also current pneumococcal 
vaccination indications included age (OR=1.03), chronic heart failure (OR=1.5), corticosteroid 
use within 30 days of positive culture (OR=1.3), dialysis (OR=3.35), metastatic malignancy 
(OR=2.54) and non-metastatic malignancy (OR=2.34), mild hepatic disease (OR=1.63) and 
moderate to severe hepatic disease (OR=2.47), myocardial infarction (OR=1.75), and 
neutropenia (OR=2.67). 
 
Significant predictors of mortality present within 1 year of culture that are not ACIP vaccination 
recommendations included cerebrovascular disease (Table 2; OR=1.25), chronic pressure ulcers 
(OR=2.04), Elixhauser comorbidity score (OR=1.16), fluid or electrolyte disorders (OR=1.20), 
Gram-negative infections (OR=1.48), methicillin-resistant Staphylococcus aureus (MRSA) 
infections (OR=1.59), neurologic disorders (OR=1.28), and weight loss (OR=1.21). Significant 
predictors present during hospitalization included cardiac arrhythmias (OR=1.41), chronic 
pressure ulcers (OR=1.42), coagulopathies (OR=2.30), dementia (OR=1.80), endocarditis 
(OR=2.74), fluid or electrolyte disorders (OR=1.69), neurologic disorders (OR=1.86), and 
vancomycin-resistant Enterococcus species infection (OR=3.78). 
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DISCUSSION 
This study identified independent predictors of 30-day all-cause mortality among unvaccinated 
adults aged 50 years and older with serious pneumococcal disease. Current literature related to 
mortality among patients with pneumococcal infections is primarily limited to patients with 
invasive pneumococcal disease, excluding nonbacteremic pneumonia.15–23 Furthermore, several 
of these studies’ cohorts excluded immunocompetent patients.21–23 Based on currently available 
literature, this study is the first to provide insight into predictors of mortality in a large real-world 
sample of patients, in particular older Veterans, with invasive and non-invasive pneumococcal 
disease. 
 
Risk of developing pneumococcal disease is highest in adults aged 65 years and older, 
immunocompromised individuals, and those with chronic illnesses, including diabetes, chronic 
lung disease, chronic heart disease, liver disease, and alcoholism.24 As such, ACIP recommends 
that these populations be vaccinated against pneumococcal disease. Pneumococcal vaccination 
prevents incident infection and, as such, has led to a reduction in negative infection-related 
outcomes, including mortality.25–27 
 
Despite the established benefits of pneumococcal vaccination, multiple studies have identified 
that current pneumococcal vaccination rates are far below the Healthy People 2020 goals.11,28 In 
2013, the National Health Interview Survey indicated that approximately 67 million at-risk 
individuals in the U.S. have not received pneumococcal vaccination, placing them at an 
increased risk of worse outcomes and more severe pneumococcal infection.5,29 This is 
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concerning, as previous research has demonstrated that people with ACIP indications for 
pneumococcal vaccination are twice as likely to die as those without indications if they develop 
invasive pneumococcal disease.30  
 
Not surprisingly, several (41%, 14/34) of the predictors of mortality identified are consistent 
with conditions that also increase the risk for development of invasive pneumococcal disease, 
and thus support current ACIP recommendations for the vaccination of adults against 
pneumococcal disease.31–33 Although pneumococcal vaccination is primarily intended to prevent 
development of disease, a recent study demonstrated that implementation of programs to 
increase vaccination with both the 23-valent polysaccharide pneumococcal vaccine and the 13-
valent pneumococcal conjugate vaccine have resulted in not only decreased incidence of invasive 
pneumococcal disease but also mortality.26 Vaccination strategies utilizing both vaccines may 
minimize negative outcomes, including mortality. 
 
In addition to conditions already identified by ACIP, this study also revealed several other 
predictors of mortality that are not current recommendations for pneumococcal vaccination. 
These included neurologic disorders, fluid or electrolyte disorders, chronic pressure ulcers, and 
MRSA or Gram-negative infections. In particular, patients with neurologic disorders, including 
seizure disorders, multiple sclerosis, Parkinson disease, and ataxia, warrant consideration. A 
recent literature review demonstrated that epilepsy, Parkinson disease, and multiple sclerosis 
were all risk factors for the development of community-acquired pneumonia, increasing risk by 
twofold to fourfold.34 Neurologic disorders are believed to increase the risk of developing 
pneumococcal disease owing to a higher likelihood of aspiration.2 As neurologic disorders were 
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also independent predictors of mortality in this study, and considering the infection and potential 
mortality prevention afforded by pneumococcal vaccination, further studies assessing the impact 
of pneumococcal vaccination on outcomes in patients with a history of neurologic disorders are 
warranted.25–27,33 
 
Fluid and electrolyte disorders, chronic pressure ulcers, and MRSA or Gram-negative infections 
were also predictive of mortality. Fluid and electrolyte disorders, which may also be related to 
renal dysfunction, were predictive both during hospitalization as well as within 1 year of culture. 
Other studies have previously demonstrated the risk of mortality associated with renal 
impairment of all severities.35,36 However, upon further analysis of the results of this study, 
diagnosis codes for renal dysfunction were present less than 20% of the time when fluid and 
electrolyte disorders were also present. Thus, mortality in patients with fluid and electrolyte 
disorders may be linked to conditions not related to renal impairment, although determining 
these associations is difficult solely based on diagnosis codes. More research regarding fluid and 
electrolyte disorders and pneumococcal disease outcomes is needed. 
 
Chronic pressure ulcers, though predictive of mortality in this study, have also been shown to be 
predictive of mortality regardless of pneumococcal infection.37 A study of 258 hospitalized 
patients demonstrated that risk of death more than tripled in the setting of pressure ulcers.37 As 
such, the findings from this study of increased mortality in patients with pressure ulcers likely 
demonstrate the frail nature of older patients. With regard to history of either MRSA or Gram-
negative infections, a plausible association with mortality is difficult to establish, as these 
diagnosis codes encompassed infections of all sources and severities. 
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This study also demonstrated that dementia was predictive of mortality. Dementia has been 
shown to increase risk of developing pneumococcal infection as well as increased disease 
severity, likely due to an increased risk of aspiration similar to neurologic disorders.2,34,38 A 
retrospective study of more than 1,000 patients with a mean age of 64 years showed that 
dementia was an independent predictor of increased pneumococcal infection severity (OR=4.23, 
95% CI=1.24, 14.4), but was not a significant predictor of mortality.38 However, severe 
infection, which was assessed in the aforementioned study as well as in this study via invasive 
disease and intensive care unit treatment, was predictive of mortality. Although dementia was 
only significant in the predictive model during hospitalization, the results of this study support 
the already identified association between dementia and poor outcomes in the setting of 
pneumococcal infection. Furthermore, at least 4% of patient’s with Alzheimer dementia, the 
most common type of dementia, are younger than age 65 years, and therefore not covered by the 
ACIP vaccination recommendation for individuals aged 65 years and older.39 Thus, 
pneumococcal vaccination may minimize poor outcomes and prevent infection in this at-risk 
population; however, further research is warranted. 
 
The strongest and most prevalent predictors of mortality were those consistent with organ 
dysfunction or immunodeficiency during the admission. Predictors that were present within 1 
year of the infection appear to have an attenuated effect on mortality in relation to those 
predictors present during the index admission. Examples of this attenuation include metastatic 
malignancy, hepatic dysfunction of all severities, myocardial infarction, and neurologic 
disorders. This may be reflective of exacerbated or poorly controlled chronic conditions, such as 
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hepatic dysfunction, in the setting of infection. Other complications, including myocardial 
infarction, have been shown to be strong predictors of short-term mortality in the setting of 
pneumonia, with increased risk of mortality still present at 1 year.6 As such, the attenuated but 
still present risk of mortality attributable to myocardial infarction in this study may reflect an 
overall poor prognosis of this group of patients. 
 
Limitations 
There were several limitations to this study. This study did not account for resistant S. 
pneumoniae isolates or the impact of antibiotic treatment on 30-day mortality. However, a 
mortality rate of 14% for pneumonia and 24% for invasive disease in this study is similar to that 
reported for elderly and hospitalized individuals reported in the literature.1,2,6,7 As such, it is 
likely that the majority of patients in this cohort received appropriate antibiotic therapy. Also, the 
number of cases of pneumonia identified likely underestimates the actual number of cases, as the 
inclusion criteria for this study required both a diagnosis code and positive sputum culture. Next, 
although patients who received a pneumococcal vaccine within 5 years of infection were 
excluded, some patients may have been vaccinated prior to that 5-year period. Others have used 
this same definition as the impact of vaccination beyond 5 years in an elderly population is 
controversial, as the elderly exhibit decreased antibody activity over time against S. pneumoniae 
after vaccination.40,41 Further, it is possible that some patients did not report vaccinations they 
received outside of the Veterans Affairs healthcare system to their Veterans Affairs provider; 
however, this potential misclassification is likely to be low, as the vaccination rate in the overall 
Veterans Affairs cohort with pneumococcal infection was similar to a community population 
with serious pneumococcal infections (33% vs 38%).42 Extrapolation of these results to the 
general population is also limited, as the population primarily consisted of older white men. 
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Furthermore, the Veteran population is generally considered to have poorer health status in 
comparison with the general population, which may also limit generalizability.43 Lastly, benefits 
from herd immunity through vaccination of children against pneumococcal disease could not be 
determined in this study. 
 
CONCLUSIONS 
This study identified independent predictors of mortality in a large cohort of unvaccinated 
Veterans with serious pneumococcal disease. These included several conditions that are already 
recognized by ACIP as recommendations for vaccination, including organ dysfunction and 
immunodeficiency. These results also suggest that individuals with neurologic disorders or 
dementia may also benefit from pneumococcal vaccination; however, further research is 
warranted. 
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Table 1. Population Demographics and Characteristics of Hospitalized, Unvaccinated Patients 
With Severe Pneumococcal Infections 
Demographic/Characteristic 
Alive at 30 days 
Died within 30 
days 
p-valuea (n=7,966) (n=1,764) 
Age (years), mean (SD) 67 (±11) 71 (±11) <0.01 
Male gender 7,795 (97.9) 1,740 (98.6) 0.03 
Race 
American Indian 98 (1.2) 14 (0.8) 0.12 
Asian or Pacific Islander 63 (0.8) 11 (0.6) 0.46 
Black 1,054 (13.2) 238 (13.5) 0.77 
White 6,297 (79.0) 1,354 (76.8) 0.03 
Unknown 454 (5.7) 147 (8.3) <0.01 
Region of facility 
Midwest 1,996 (25.1) 382 (21.7) <0.01 
Northeast 1,147 (14.4) 290 (16.4) 0.03 
South 2,766 (34.7) 695 (39.4) <0.01 
West 2,057 (25.8) 397 (22.5) <0.01 
Treating specialty 
Intensive care unit 1,830 (23.0) 699 (39.6) <0.01 
Current pneumococcal infection 
Pneumonia 5,204 (65.3) 871 (49.4) <0.01 
Bacteremia 1,969 (24.7) 585 (33.2) <0.01 
Pneumonia and bacteremia 755 (9.5) 305 (17.3) <0.01 
Invasive pneumococcal infectionb 2,762 (34.7) 893 (50.6) <0.01 
Other infections during admissionc 
Infective arthritis 41 (0.5) <5 0.02 
Infective endocarditis 27 (0.3) 14 (0.8) <0.01 
Skin or soft tissue infection 336 (4.2) 114 (6.5) <0.01 
Urinary tract infection 371 (4.7) 133 (7.5) <0.01 
Other positive cultures during admission 
E. coli 61 (0.8) 17 (1.0) 0.4 
Gram-negative organisms 149 (1.9) 60 (3.4) <0.01 
MRSA 106 (1.3) 29 (1.6) 0.31 
MSSA 139 (1.7) 57 (3.2) <0.01 
Pseudomonas spp. 104 (1.3) 37 (2.1) 0.01 
Vancomycin-resistant Enterococcus spp. 6 (0.1) 7 (0.4) <0.01 
Comorbidities during admission 
Alcohol abuse 734 (9.2) 147 (8.3) 0.24 
Amputation 52 (0.7) 5 (0.3) 0.07 
Cardiac arrhythmia 1,496 (18.8) 503 (28.5) <0.01 
Cerebrovascular disease 317 (4.0) 124 (7.0) <0.01 
Chronic renal disease 584 (7.3) 195 (11.1) <0.01 
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Chronic respiratory disease 3,106 (39.0) 579 (32.8) <0.01 
Coagulopathy 267 (3.4) 138 (7.8) <0.01 
Coronary artery disease 1,370 (17.2) 336 (19.0) 0.06 
Dementia 109 (1.4) 59 (3.3) <0.01 
Diabetes mellitus 1,256 (15.8) 252 (14.3) 0.12 
Dialysis 150 (1.9) 104 (5.9) <0.01 
Drug abuse 340 (4.3) 30 (1.7) <0.01 
Fluid or electrolyte disorders 1,649 (20.7) 455 (25.8) <0.01 
Heart failure 1,040 (13.1) 334 (18.9) <0.01 
Hepatic disease, mild 404 (5.1) 140 (7.9) <0.01 
Hepatic disease, moderate or severe 64 (0.8) 57 (3.2) <0.01 
Hypertension 2,544 (31.9) 453 (25.7) <0.01 
Metastatic malignancy 227 (2.8) 158 (9.0) <0.01 
Neurological disorders 326 (4.1) 133 (7.5) <0.01 
Neutropenia 23 (0.3) 23 (1.3) <0.01 
Obesity 1,894 (23.8) 292 (16.6) <0.01 
Chronic pressure ulcer 197 (2.5) 92 (5.2) <0.01 
Infection previous year 
Bacteremiac 217 (2.7) 109 (6.2) <0.01 
Pneumococcal infectiond 2,256 (28.3) 686 (38.9) <0.01 
Pneumoniac 1,911 (24.0) 625 (35.4) <0.01 
Skin or soft tissue infectionc 856 (10.7) 281 (15.9) <0.01 
Urinary tract infectionc 583 (7.3) 266 (15.1) <0.01 
Positive cultures within previous year 
E. coli 78 (1.0) 43 (2.4) <0.01 
Gram-negative organisms 141 (1.8) 71 (4.0) <0.01 
MRSA 122 (1.5) 67 (3.8) <0.01 
MSSA 201 (2.5) 109 (6.2) <0.01 
Pseudomonas spp. 127 (1.6) 53 (3.0) <0.01 
Vancomycin-resistant Enterococcus spp. 6 (0.1) 7 (0.4) 0.51 
Medical history 
Alcohol abuse 1,261 (15.8) 313 (17.7) 0.05 
Amputation 114 (1.4) 39 (2.2) 0.02 
Cardiac arrhythmia 1,707 (21.4) 592 (33.6) <0.01 
Cerebrovascular disease 770 (9.7) 301 (17.1) <0.01 
Chronic renal disease 668 (8.4) 266 (15.1) <0.01 
Chronic respiratory disease 3,609 (45.3) 911 (51.6) <0.01 
Coagulopathy 359 (4.5) 184 (10.4) <0.01 
Coronary artery disease 1,999 (25.1) 611 (34.6) <0.01 
Dementia 182 (2.3) 113 (6.4) <0.01 
Diabetes mellitus 1,709 (21.5) 476 (27.0) <0.01 
Dialysis 66 (0.8) 33 (1.9) <0.01 
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Drug abuse 636 (8.0) 118 (6.7) 0.07 
Fluid or electrolyte disorders 1,566 (19.7) 625 (35.4) <0.01 
Heart failure 1,324 (16.6) 489 (27.7) <0.01 
Hepatic disease, mild 590 (7.4) 241 (13.7) <0.01 
Hepatic disease, moderate or severe 115 (1.4) 79 (4.5) <0.01 
Hypertension 3,952 (49.6) 1,035 (58.7) <0.01 
Immunocomproming conditione 2,535 (31.8) 747 (42.3) <0.01 
Metastatic malignancy 382 (4.8) 239 (13.6) <0.01 
Neurological disorders 522 (6.6) 220 (12.5) <0.01 
Neutropenia 28 (0.4) 19 (1.1) <0.01 
Pressure ulcer 334 (4.2) 175 (9.9) <0.01 
Receiving immunocompromising 
medicationf 1,795 (22.5) 498 (28.2) <0.01 
Cigarette smoking 3,777 (47.4) 674 (38.2) <0.01 
Elixhauser comorbidity index, median (IQR) 3 (1-5) 4 (3-6) <0.01 
Length of stay (days), median (IQR) 6 (3-13) 8 (3-15) <0.01 
Note: Boldface indicates statistical significance (p<0.05). 
a Chi-square or Fisher’s Exact test, as appropriate. 
b Includes bacteremia, pneumonia and bacteremia, meningitis, bacteremia and meningitis, and 
pneumonia, bacteremia, and meningitis 
c Attributed to any organism. 
d Includes all infection types from any positive Streptococcus pneumoniae culture site. 
e HIV, AIDS-defining illness, solid malignancy, or hematologic malignancy within 1 year of 
positive S. pneumoniae culture. 
f Received corticosteroid, monoclonal antibody, or antineoplastic agent within 30 days of 
positive Streptococcus pneumoniae culture 
IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, 
methicillin-sensitive Staphylococcus aureus; spp., species 
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Table 2. Predictors of 30-Day All-Cause Mortality in Unvaccinated Patients With Severe Pneumococcal Disease 
Predictor 
Predictors during hospitalization Predictors within 1 year 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Pneumococcal vaccine currently recommended 
Age 1.03 (1.02-1.03) 1.03 (1.03-1.04) - - 
Congestive heart failure 1.56 (1.36-1.78) 1.50 (1.25-1.81) - - 
Corticosteroid use within 30 
days of culture - - 1.27 (1.12-1.43) 1.3 (1.13-1.50) 
Dialysis 3.27 (2.53-4.22) 3.35 (2.37-4.72) - - 
Metastatic malignancy 3.35 (2.72-4.14) 2.54 (1.89-3.41) 3.11 (2.62-3.69) 1.53 (1.19-1.97) 
Mild liver disease 1.61 (1.32-1.97) 1.63 (1.20-2.22) 1.98 (1.69-2.32) 1.35 (1.07-1.71) 
Moderate or severe liver disease  4.12 (2.87-5.91) 2.47 (1.53-3.99) 3.20 (2.39-4.28) 1.49 (1.01-2.20) 
Myocardial Infarction 2.08 (1.67-2.58) 1.75 (1.35-2.27) 2.08 (1.74-2.48) 1.31 (1.06-1.62) 
Neutropeniaa 4.56 (2.55-8.15) 2.67 (1.32-5.42) - - 
Non-metastatic malignancy 2.21 (1.95-2.50) 2.34 (1.91-2.87) - - 
Pneumococcal vaccine not currently recommended 
Cardiac arrhythmia 1.73 (1.53-1.94) 1.41 (1.21-1.63) - - 
Cerebrovascular disease - - 1.92 (1.66-2.22) 1.25 (1.05-1.49) 
Chronic pressure ulcers 2.17 (1.69-2.80) 1.42 (1.04-1.92) 2.15 (2.08-3.05) 2.04 (1.48-2.82) 
Coagulopathy 2.45 (1.98-3.03) 2.3 (1.75-3.01) - - 
Dementia 2.49 (1.81-3.44) 1.80 (1.23-2.61) - - 
Elixhauser comorbidity score - - 1.19 (1.17-1.21) 1.16 (1.12-1.20) 
Endocarditis 2.35 (1.23-4.50) 2.74 (1.28-5.90) - - 
Fluid or electrolyte disorders 1.33 (1.18-1.50) 1.69 (1.43-1.99) 2.24 (2.01-2.51) 1.20 (1.03-1.39) 
Gram-negative infection - - 2.33 (1.74-3.11) 1.48 (1.05-2.07) 
MRSA infection - - 2.54 (1.88-3.44) 1.59 (1.12-2.25) 
Neurological disorders 1.91 (1.55-2.35) 1.86 (1.42-2.45) 2.03 (1.72-2.40) 1.28 (1.02-1.59) 
Vancomycin-resistant 
Enterococcus spp. infection 5.28 (1.77-15.74) 3.78 (1.02-14.17) - - 
Weight loss - - 2.06 (1.79-2.37) 1.21 (1.02-1.44) 
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Other predictors 
Hospital admission in 
northeastern U.S. 1.31 (1.11-1.55) 1.29 (1.06-1.56) - - 
Hospital admission in southern 
U.S. 1.30 (1.14-1.49) 1.33 (1.14-1.56) - - 
ICU level of care 2.20 (1.97-2.45) 2.26 (1.99-2.57) - - 
Invasive pneumococcal disease 1.93 (1.74-2.14) 2.1 (1.85-2.39) - - 
Notes: Final multivariable logistic regression model included 54 variables (194 variables assessed). Significant variables during 
admission in the final model (OR<1): length of stay, Elixhauser comorbidity score, hypertension, streptococcal spp. infection, 
amputation, infective arthritis. Significant variables within previous year in the final model (OR<1): history of peripheral vascular 
disease, cigarette smoking, drug abuse, dialysis. Other variables included in the final model (OR<1): obesity, race, hospital admission 
in the midwestern and western U.S. (reference). 
a Neutropenia may be classified as an immunocompromising condition, which was a recommendation for PPSV-23 vaccination in 
1984. 
 
Adjusted, results of multivariable logistic regression; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; 
Unadjusted, results of univariable logistic regression 
 
